Compare ATOM & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | KALA |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.2M | 172.0M |
| IPO Year | 2016 | 2017 |
| Metric | ATOM | KALA |
|---|---|---|
| Price | $8.81 | $0.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 2.2M | ★ 2.9M |
| Earning Date | 05-05-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.41 | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,000.00 | N/A |
| Revenue This Year | $527.69 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $0.14 |
| 52 Week High | $9.59 | $20.58 |
| Indicator | ATOM | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 79.31 | 29.58 |
| Support Level | $2.20 | N/A |
| Resistance Level | N/A | $0.24 |
| Average True Range (ATR) | 0.76 | 0.02 |
| MACD | 0.32 | 0.00 |
| Stochastic Oscillator | 84.13 | 2.06 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.